Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium- or high-dose inhaled corticosteroids.

abstract：:Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

journal_title：Drugs

authors： Johnson MR,Lydiard RB,Ballenger JC

更新日期：1995-03-01 00:00:00

abstract：:Endothelial dysfunction and increased arterial stiffness occur early in the pathogenesis of diabetic vasculopathy. They are both powerful independent predictors of cardiovascular risk. Advances in non-invasive methodologies have led to widespread clinical investigation of these abnormalities in diabetes mellitus, gene...

journal_title：Drugs

authors： Woodman RJ,Chew GT,Watts GF

更新日期：2005-01-01 00:00:00

abstract：:A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficac...

journal_title：Drugs

authors： Pleasants RA,Wang T,Gao J,Tang H,Donohue JF

更新日期：2016-03-01 00:00:00

abstract：:The potential beneficial effects of antihypertensive drugs on cardiovascular morbidity and mortality may be compromised by their adverse effects on serum lipid levels. In our study we compared verapamil and captopril and evaluated their effects on blood pressure and on serum lipid and lipoprotein levels, with particul...

journal_title：Drugs

authors： Catalano M,Cislaghi C,Carzaniga G,Aronica A,Seregni R,Libretti A

更新日期：1992-01-01 00:00:00

abstract：:The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...

journal_title：Drugs

authors： Epstein BJ,Gums JG

更新日期：2005-01-01 00:00:00

abstract：:Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...

journal_title：Drugs

authors： Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

更新日期：1975-01-01 00:00:00

abstract：UNLABELLED:Ofloxacin is an established fluoroquinolone agent which achieves good concentrations in genitourinary tract tissues and fluids. It has good in vitro activity against most Enterobacteriaceae, Staphylococcus saprophyticus, methicillin-susceptible S. aureus, Neisseria gonorrhoeae, Chlamydia trachomatis and Haem...

journal_title：Drugs

authors： Onrust SV,Lamb HM,Balfour JA

更新日期：1998-11-01 00:00:00

abstract：:Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...

journal_title：Drugs

authors： Viberti G

更新日期：2003-01-01 00:00:00

abstract：:Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

journal_title：Drugs

authors： Scott LJ,Keam SJ

更新日期：2021-01-06 00:00:00

abstract：:Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...

journal_title：Drugs

authors： Robinson DM,Scott LJ,Plosker GL

更新日期：2006-01-01 00:00:00

abstract：:Tofacitinib (Xeljanz®) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are int...

journal_title：Drugs

authors： Dhillon S

更新日期：2017-12-01 00:00:00

abstract：:Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...

journal_title：Drugs

authors： Deget F,Brogden RN

更新日期：1991-05-01 00:00:00

abstract：:Since an earlier review in the Journal substantial additional data have accumulated, further clarifying the in vitro activity, pharmacokinetic profile, clinical efficacy and tolerability of teicoplanin. Recent therapeutic trials confirm the efficacy of teicoplanin in the treatment of microbiologically confirmed Gram-p...

journal_title：Drugs

authors： Brogden RN,Peters DH

更新日期：1994-05-01 00:00:00

abstract：:Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for L-type calcium channels that has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that, in 95 patients with mild-to-moderate hypertension, long-term treatment with a...

journal_title：Drugs

authors： Wellington K,Scott LJ

更新日期：2003-01-01 00:00:00

abstract：:Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome ...

journal_title：Drugs

authors： Plosker GL,Clissold SP

更新日期：1992-03-01 00:00:00

abstract：:A study was made of the clinical features and therapeutic response of 144 patients from whose sputum Branhamella catarrhalis was isolated. Typically, features of bronchopulmonary infection with cough productive of moderate amounts of purulent sputum, fever and dyspnoea were present. Of 74 patients who were infected in...

journal_title：Drugs

authors： McLeod DT,Ahmad F,Croughan MJ,Calder MA

更新日期：1986-01-01 00:00:00

abstract：:Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...

journal_title：Drugs

authors： Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

更新日期：1982-09-01 00:00:00

abstract：:The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

journal_title：Drugs

authors： Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

更新日期：1985-01-01 00:00:00

abstract：:Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...

journal_title：Drugs

authors： Willkens RF

更新日期：1990-01-01 00:00:00

abstract：:Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...

journal_title：Drugs

authors： Lecarpentier E,Morel O,Fournier T,Elefant E,Chavatte-Palmer P,Tsatsaris V

更新日期：2012-04-16 00:00:00

abstract：:Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...

journal_title：Drugs

authors： Stokes GS

更新日期：1976-01-01 00:00:00

abstract：:Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

journal_title：Drugs

authors： Markham A

更新日期：2016-07-01 00:00:00

abstract：:Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common...

journal_title：Drugs

authors： Perry CM,Scott LJ

更新日期：2004-01-01 00:00:00

abstract：:Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2019-06-01 00:00:00

abstract：OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

journal_title：Drugs

authors： Becker A

更新日期：2000-01-01 00:00:00

abstract：:During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic b...

journal_title：Drugs

authors： Diasio RB

更新日期：1999-01-01 00:00:00

abstract：:The Japanese encephalitis vaccine IC-51 (IXIARO) is an inactivated virus (strain SA(14)-14-2) that is manufactured in cultured Vero cells and is currently being developed for preventive vaccination against the Japanese encephalitis virus. black triangle Administration of IXIARO as a two-dose treatment in healthy adult...

journal_title：Drugs

authors： Duggan ST,Plosker GL

更新日期：2009-01-01 00:00:00

abstract：:Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...

journal_title：Drugs

authors： Scott LJ

更新日期：2018-09-01 00:00:00

abstract：:Cephalosporins have a role in the treatment of gonorrhoea, and especially infections caused by strains that are penicillin-resistant, either because they produce plasmid-mediated beta-lactamase or they have chromosomally mediated diminished permeability or modified penicillin-binding proteins. Although none of the ora...

journal_title：Drugs

authors： Phillips I

更新日期：1987-01-01 00:00:00

abstract：:The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...

journal_title：Drugs

authors： Ferrari R,Visioli O

更新日期：1991-01-01 00:00:00